Neutrophils Promote Tumor Progression in Oral Squamous Cell Carcinoma by Regulating EMT and JAK2/STAT3 Signaling Through Chemerin

Xiaoyuan Hu1,2, Fenggang Xiang1,3, Yuanyong Feng1,4, Fei Gao7, Shengyou Ge1,4, Chengqin Wang1,3, Xuan Zhang1 and Ning Wang1*

1 Department of Pathology, School of Basic Medicine, Medical College of Qingdao University, Qingdao, China, 2 Department of Pathology, Pingxiang People’s Hospital, PingXiang, China, 3 Department of Pathology, the Affiliated Hospital of Qingdao University, Qingdao, China, 4 Department of Oral and Maxillofacial Surgery, School of Stomatology and The Affiliated Hospital of Qingdao University, Qingdao, China

Oral squamous cell carcinoma (OSCC) is the most common malignancy of the oral cavity. In the tumor microenvironment, tumor-associated neutrophils (TANs) can promote tumor growth, invasion, and metastasis. The aim of our study was to explore the relationship between neutrophils infiltration and Chemerin expression in tumor cells, as well as their relationship with the clinicopathological parameters and clinical prognosis of 74 cases of OSCC. We also explored the role of the interaction between neutrophils and Chemerin in the functions of OSCC cells (Cal27, SCC9, and SCC15) in vitro. Our results showed that in OSCC, Chemerin over-expression may increase neutrophils infiltration in tumor tissues. Chemerin over-expression and neutrophils infiltration were the prognostic factors of poor clinical outcomes. Furthermore, we discovered that neutrophils promoted OSCC migration, invasion, and proliferation and EMT through Chemerin. Neutrophils activated JAK2/STAT3 signaling through Chemerin and then up-regulated its downstream signaling target genes, such as Phospho-Rb, E2F1, CyclinE1, and CyclinD1. Taken together, our results revealed that neutrophils and Chemerin are potentially involved in OSCC progression and metastasis. Neutrophils may promote the JAK2/STAT3 signaling pathway and EMT in OSCC cells through Chemerin.

Keywords: chemerin, oral squamous cell carcinoma, neutrophils, JAK2/STAT3, EMT, tumor progression

INTRODUCTION

Oral squamous cell carcinoma (OSCC) is the most common malignancy of the oral cavity (1). Although treatment methods, such as chemotheraphy, radiotherapy, and surgical therapy, have advanced in recent years, the 5-year survival rate of patients with OSCC has remained less than 60% (2). The mechanisms of the occurrence and development of OSCC are still unclear. However, recent studies
have shown that the interaction between tumor cells and immune cells creates a favorable microenvironment for cancer initiation, progression, and metastasis (3, 4). The cross-talk between tumor cells and immune cells may promote tumor development (4).

Recent studies have revealed that in addition to tumor cells, inflammation and the immune system, as indispensable participants in tumor formation, provide an attractive environment for tumor growth and metastasis. Neutrophils are not only the most abundant circulating white blood cells, they are also one of the main infiltrating immune and inflammatory cells in OSCC (5). A growing body of research has demonstrated that tumor-associated neutrophils (TANs), a predominant component of the tumor microenvironment, participate in tumor initiation, growth, proliferation, and metastatic spread (6). In accordance with different tumor microenvironments and in addition to the contact mechanism, TANs can induce the paracrine release of cytokines and chemokines with tumor-promoting or anti-tumor functions to affect tumor progression (7). Evidence showing that increased TANs infiltration is associated with poor clinical outcomes in OSCC exists (8, 9). These novel aspects of neutrophils biology may contribute to OSCC progression and metastasis. However, only a few studies have been done on the specific signaling pathways and molecular mechanisms involved in the interaction between neutrophils and OSCC (10).

EMT is a key event where in epithelial cells lose their epithelial characteristics and acquire a mesenchymal phenotype (11). Its phenotypic transition is manifested as the loss of cell polarity and cell–cell connection and the acquisition of mesenchymal characteristics, such as motility and invasiveness, by epithelial cells (12). At the molecular level, it usually manifests as the decreased expression of E-cadherin and the increased expression of N-cadherin, mesenchymal markers (vimentin), and transcription factors (Slug and Snail) (12–14). Recent studies have illustrated that EMT plays a vital role in tumor progression and metastasis (15–17). Stromal cells in the tumor microenvironment can induce EMT. Neutrophils constitute an important part of tumor stroma, and they are mainly involved in regulating tumor progression (6, 18). However, studies on neutrophils function in EMT and its possible molecular mechanisms remain rare.

Chemerin, an effective chemoattractant protein encoded by retinoic acid receptor responder 2, was first discovered in psoriatic skin lesions (19, 20). Recent studies have revealed that the expression of Chemerin is dysregulated in several types of tumors. Chemerin expression is up-regulated in neuroblastoma, esophageal squamous cell carcinoma, and OSCC (20–22) but is down-regulated in hepatocellular carcinoma and adrenocortical carcinoma (23, 24). Weigert et al. (25) reported that Chemerin levels in the serum of patients with inflammatory bowel disease are elevated relative to those in the serum of healthy controls, indicating that Chemerin has a potential regulatory function in intestinal inflammation. In addition, Sotiropoulos et al. (8) reported that Chemerin, a biomarker of nonsmall cell lung cancer, is involved in tumor-promoting networks and inflammatory and cancer-related metabolic pathways.

Our previous studies demonstrated that Chemerin is over-expressed in OSCC (26), that TANs infiltration in tumor tissues is increased (9), and that both of these factors are correlated with the poor clinical outcomes of patients with OSCC (9, 22). Chemerin expression in tumor cells may play important roles in immune surveillance. However, the role of Chemerin and neutrophils in OSCC remains unknown. The JAK2/STAT3 pathway has been found to play a critical role in the progression of a variety of tumors (27–29). The expression levels of STAT3 and phosphorylated STAT3 in OSCC are increased compared with those in normal tissues (30). A number of previous findings strongly suggest that the persistent activation of STAT3 in head and neck squamous cell carcinomas, accompanied by increases in STAT3 tyrosine phosphorylation, is linked to cell proliferation, differentiation, and apoptosis (31, 32). The role of neutrophils, along with JAK2/STAT3 signaling and EMT, in OSCC has been poorly addressed. Therefore, the purpose of our work is to determine how neutrophils activate the JAK2/STAT3 pathway in OSCC and how Chemerin and neutrophils promote the migration, invasion, and proliferation of OSCC.

In the present study, we studied the relationship between TANs infiltration and Chemerin expression. We also investigated TANs infiltration and Chemerin expression in relation to clinicopathological parameters and clinical prognosis. Moreover, we explored the roles of neutrophils and Chemerin in EMT and JAK2/STAT3 signaling pathway regulation and identified the downstream targets phosphor-Rb, E2F1, CyclinD1, and CyclinE1. Our results indicated that neutrophils could regulate the JAK2/STAT3 signaling pathway and EMT through Chemerin to promote OSCC and provided support that neutrophils and Chemerin are potential therapeutic targets for the treatment of OSCC.

MATERIAL AND METHODS

Patients and Specimens
A total of 74 patients (51 males and 23 females) with primary tongue squamous cell carcinoma treated at the Affiliated Hospital of Qingdao University between 2005 and 2010 participated in this study. The clinical pathological data of all the patients were complete, and no radiotherapy or chemotherapy was performed before surgery. The clinicopathological information of the patients is presented in Table 1. The study protocol was approved by the ethics committee of the Affiliated Hospital of Qingdao University. Written informed consent was obtained from all of the patients and healthy controls. The studies were conducted in accordance with the Declaration of Helsinki.

Tissue Microarray and Double Staining Immunohistochemistry
The tissue microarray (TMA) used in this work was constructed as follows: First, representative areas located away from necrotic and hemorrhagic materials were premarked in paraffin-embedded wax blocks via H&E staining. Triplicates of 1-mm
diameter cylinders from the centers of the tumors of 74 cases and the peritumoral noncancerous squamous epithelial tissues of 17 cases (designated as tumor and peritumoral tissues, respectively) were included in the TMA. Thus, several different TMA blocks were constructed. The blocks then were sectioned to a thickness of 4 µm and placed on slides that were coated with 3-aminopropyltriethoxysilane for immunohistochemistry (IHC).

A polymer double-staining kit (Zhongshan Golden Bridge Biotech, China) was used for staining. After the deparaffinization and gradient ethanol hydration of the sections, endogenous enzymes were inactivated by using 3% H₂O₂ for 30 min. The sections were boiled in a water bath for heat-induced epitope retrieval in EDTA buffer (95°C) and cooled naturally at room temperature. After washing with PBS, the sections were incubated with anti-Chemerin (dilution of 1:100, Proteintech, China) or anti-CD15 (dilution of 1:150) antibodies overnight at 4°C in a humidity chamber. The polymer horseradish peroxidase detection system (ZSGB, China) in this work used DAB and GBI for visualization and hematoxylin for nuclear counter staining. The results showed that DAB-stained CD15+ was brown, GBI-stained Chemerin was red, and hematoxylin-stained cell nuclei were blue.

**Immunostaining**

The evaluation criteria for the IHC results were as previously reported (6). Chemerin staining was evaluated on the basis of a semiquantitative scoring system. The intensity score represented the average intensity of the positive tumor cells (0, none; 1, weak; 2, intermediate; and 3, strong) (20). The proportion score represented the estimated proportion of positive tumor cells: 0: (<5%), 1: (5%–25%), 2: (26%–50%), 3: (51%–75%), and 4: (>75%). The proportion and intensity scores were then added to obtain a total score, which ranged from 0 to 7. All specimens were divided into two groups: weak expression, 0–3 points and strong expression, 4–7 points. For the CD15+ neutrophil count, positive cells in three cylinders with a diameter of 1 mm per patient were calculated and presented as the mean value of the triplicates (cells/core). The average value of CD15+ neutrophils in TMA was acquired, and the median of CD15+ neutrophils of each experimental group/neutrophils count of the control patient were calculated and presented as the mean value of the triplicates (cells/core).

If the mean number of the triplicates was more than the median, the specimen was allocated into the high-density group and into the low-density group otherwise.

The specimens were divided into three groups to evaluate the expression of Chemerin and CD15+TANs density: the strong Chemerin expression+ high TANs density group (@1), the strong Chemerin expression+ low TANs density group/weak Chemerin expression+ high TANs density group (@2), and the weak Chemerin expression+ low TANs density group (@3).

**Cell Culture**

OSCC lines (Cal27, SCC9, and SCC15) were purchased from Shanghai Institutes for the Chinese Academy of Sciences and cultured at 37°C in a humidified atmosphere of 5% CO₂ in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% FBS with 1% penicillin–streptomycin. For co-cultivation studies, 1 × 10⁶ OSCC cells and neutrophils (1:3 ratio) seeded 24 h before co-cultivation were added to the upper chamber of a Transwell chamber with a 0.4-µm porous polycarbonate membrane (Corning, Union City, CA, USA) or to the lower chamber. The OSCC cells were collected after 24–48 h.

**Extraction of Neutrophils From Peripheral Blood**

Neutrophils were isolated from peripheral blood of healthy donors at the Affiliated Hospital of Qingdao University after written informed consent was obtained. In a 15 ml centrifuge tube, 5.0 ml of anticoagulated whole blood was layered on 5.0 ml of PolymorphPrep (Axis-Shield PoC AS, Norway). After centrifugation at 450 × g for 30 min, the mononuclear cell phase was discarded to isolate neutrophils. After centrifugation, two bands of white blood cells were obtained. The top band consisted of mononuclear cells, and the lower band consisted of polymorphonuclear neutrophils (PMNs). All the cell bands were collected, and the remaining RBCs were lysed with a hypotonic lysis program to obtain the pure PMNs population.

**Transwell Chemotaxis Assay**

The cell chemotaxis assay was performed in a 24-well Transwell chamber with a polycarbonate membrane with a 3 mm pore size (Corning, USA). A total of 2 × 10⁵ neutrophils were suspended in 200 µl of serum-free medium in each upper compartment. Then, 600 µl of RPMI-1640 with 10% serum containing recombinant Chemerin (20, 50, 100, or 200 ng/ml) or 2 × 10⁵ OSCC cells (Cal27, SCC9, and SCC15) was added to the lower compartment. RPMI-1640 with 10% serum was added to the lower compartment of the control group. After incubation at 37°C for 24 h, the suspended neutrophils in the lower compartment were counted by using a cell counting plate. The chemotactic index for each group was calculated as follows: neutrophils count of each experimental group/neutrophils count of the control group × 100%.

**Enzyme-Linked Immunosorbent Assay**

The concentration of Chemerin in the medium was measured via an enzyme-linked immunosorbent assay (ELISA, R&D Systems, USA) in accordance with the manufacturer’s instructions.

**Lentiviral Transduction**

Lentiviruses were synthesized by GenePharma (Suzhou, China). The sequences of Chemerin-shRNA and scramble controls were as follows: Chemerin-shRNA1#, 5′-GCCCTTCCAGCTGG AAAATT-3′; Chemerin-shRNA2#, 5′-GCTTCTACTTCCCTG GACGAT-3′; negative control (Scr-shRNA), 5′-ACGUG ACACGUCCGAGAATTDT-3′. Chemerin was over-expressed by using an over-expression vector plasmid (Chemerin). Empty plasmids were used as the negative control (NC). Plasmids were purchased from GenePharma (GenePharma, China).

**Cell Viability Assay**

For the cell co-culture, 3 × 10⁵ OSCC cells were seeded into each well of 96-well plates in the presence or absence of neutrophils...
(1:3 ratio). After 24 h, the neutrophils were removed from the co-culture system. Subsequently, methylthiazolyldiazotetrazole (MTT) measurements were performed at different time points (0, 24, 48, 72, and 96 h). A total of 20 µl of MTT (5 mg/ml) was added into each well, and the cells were further incubated for 4 h. Then, the media were discarded, and 150 µl of DMSO was added. The plate was shaken at room temperature for 15 min, and absorbance was read at 490 nm on an automatic microplate reader (Bio-Tek Instruments, Winooski, VT, USA).

Colony Formation Assay
After 24–48 h of co-culture or non-co-culture with neutrophils, the OSCC cells were cultured in a six-well plate at the density of 3000 cells/well for 2 weeks. The colonies that formed were fixed with methanol for 30 min and sequentially stained with 0.5% crystal violet for half an hour.

Cell Cycle Analysis
After 24–48 h of co-culture or non-co-culture with neutrophils, the OSCC cells were washed with ice-cold PBS and harvested via trypsinization. After centrifugation for 5 min, the cells were washed with ice-cold PBS and fixed with 70% ethanol overnight at 4°C. RNaseA (20 µg/ml) was added to the cells for 30 min (at 37°C). Propidium iodine (50 µg/ml) was added to the cells in the dark. The cells were analyzed by using flow cytometry (BD Accuri C6).

Cell Migration and Invasion Assay
The cell migration/invasion assay was performed in a 24-well Transwell chamber with a polycarbonate membrane with an 8 mm pore size (Corning, Union City, CA, USA). A total of 50 µl of diluted Matrigel (Matrigel: serum-free medium=1:8) was added into the upper chamber of the Transwell plates for the invasion assay, whereas the plates without Matrigel in their upper chambers were used for the migration assay. The treated cells were incubated in serum-free medium for 24 h. A total of 1.25–2.5 × 10^5 neutrophils in 500 µl of RPMI-1640 containing 15% FBS were added to the lower chamber, and 5 × 10^4 OSCC cells in 500 µl of DMEM containing 15% FBS were added to the upper chamber. After 24–48 h of incubation at 37°C, the cells that had migrated to the medium containing 15% serum in the lower compartment were stained with 0.5% crystal violet to half an hour.

Quantitative Real-Time PCR
Total RNA extraction and quantitative real-time PCR (qRT-PCR) were performed as previously described (6). Primers were synthesized by the Shanghai Sangon Biological Engineering Technology & Services Co.

The primers used in this assay were:
- Chemerin: 5′-AGACAAAGGCTGGGCAAGAGG-3′ (upper) and 5′-TGAGAAAGGCCAACTGTCCA-3′ (lower);
- GAPDH: 5′-CGGAGTCAACGGATTTGGTCGTA-3′ (upper) and 5′-AGCCTTCTCCATGGTGTTGGAAGAC-3′ (lower).

Western Blot Analysis
Protein preparation and Western blot analysis were performed as described previously (33). The antibodies used in the study were as follows: Chemerin (Abcam, dilution of 1:500), GAPDH, E-cadherin, N-cadherin, Vimentin, p-JAK2, JAK2, Phospho-Rb (Abcam, dilution of 1:1000), p-STAT3, STAT3, Phospho-Rb (Abcam, dilution of 1:2000), E2F1, Cyclin D1, Cyclin E1 (Abcam, dilution of 1:1000), Slug and Snail (ProteinTech, dilution of 1:1000), and β-actin (ProteinTech, dilution of 1:4000).

Statistical Analysis
All statistical analyses were performed by using SPSS 23.0 software. All values were presented as mean ± SD, and each experiment was performed at least three times. Mann–Whitney test was used for non-normally distributed data. Student’s t test was used for data that were normally distributed. Differences were considered statistically significant at P < 0.05, P < 0.01, and P < 0.001.

RESULTS
Immunohistochemical Analysis of TANs Infiltration and Chemerin Expression and Their Correlation With Clinicopathological Parameters
Double IHC results revealed that Chemerin and CD15+ TANs co-localized in clinical OSCC specimens. The IHC results demonstrated that CD15+ TANs infiltration in OSCC tissues (Figures 1B–D) was greater than that in peritumoral tissues (Figure 1A). TANs were predominantly observed in the stroma around carcinoma nests (Figure 1B), within carcinoma nests (Figure 1C), and in the borderline of tumor invasion (Figure 1D). Tumors with negative or weak Chemerin expression had low TANs infiltration (Figure 1E), whereas those with strong Chemerin expression had high TANs infiltration (red arrow) (Figure 1F). The number of CD15+ TANs outside the blood vessels ranged from 1 to 1053.5 in each 1-mm-diameter tissue sample. The median density was 59.5/core. If the mean number of the triplicates exceeded 59.5, the sample was allocated into the high-density group. Otherwise, it was allocated into the low-density group. In addition, the IHC results showed that in OSCC, Chemerin expression was heterogeneous. Among the 74 cases of OSCC, 25 (33.78%) had weak Chemerin expression and 49 (66.22%) had strong Chemerin expression.

In tumor tissues, strong Chemerin expression+ high TANs density was associated with high clinical stage (P < 0.001), lymph node metastasis (P < 0.001), and tumor recurrence (P = 0.01) (Table 1). As shown in Table 2, Spearman’s rho coefficient revealed that Chemerin expression was positively correlated with CD15+ TANs infiltration in OSCC (P = 0.017).

Analysis of the Influence of TANs Infiltration and Chemerin Expression on the Survival of Patients With OSCC
We followed up all 74 patients to evaluate the effect of TAN infiltration and Chemerin expression on the survival of patients...
with OSCC. The median follow-up time was 96 months. Within the observation period, 37 patients died from cancer.

Kaplan–Meier survival analysis revealed that strong Chemerin expression+ high neutrophil density (Figures 2A, B) and advanced clinical stage (Figure 2C) were associated with the short cancer-related survival of patients with OSCC. Tumor size \((P = 0.591)\), tumor differentiation \((P = 0.312)\), tumor recurrence \((P = 0.123)\), patient gender \((P = 0.597)\), and age \((P = 0.592)\) had no effect on cancer-related survival. We performed multivariate survival analysis by using a Cox proportional hazards model to analyze whether the above parameters are independent prognostic factors for the survival of patients with OSCC. The results showed that strong Chemerin expression and high CD15+ TANs density were independent prognostic factors for patients with OSCC (Tables 3 and 4).

**OSCC Cells Expressing Chemerin Attract Neutrophils In Vitro**

On the basis of the IHC results, we explored whether Chemerin can attract neutrophils *in vitro* via Transwell assay. The results of ELISAs (Figure 3A) and qRT-PCR (Figure 3B) showed that all three cell lines had a certain level of Chemerin expression and...
secretion. As depicted in Figure 3C, compared with the blank group, all three OSCC cells demonstrated improved chemotaxis to neutrophils \((P < 0.05)\). Among the three cell lines, SCC15 demonstrated the most effective chemotaxis and the highest level of Chemerin (Figures 3A–C). The chemotactic effect of the SCC15-Chemerin-shRNA group of cells on neutrophils was weaker than that of the SCC15 group. By contrast, the chemotactic effect of the SCC9-Chemerin and Cal27-Chemerin groups was stronger than that of the SCC9 and Cal27 groups. After Chemerin knockdown, the chemotactic effect of SCC15 on neutrophils weakened, and after Chemerin over-expression, that of SCC9 and Cal27 on neutrophils strengthened (Figure 3C). R-Chemerin was also used to verify the chemotactic effect of Chemerin on neutrophils. The results showed that R-Chemerin improved the chemotaxis of neutrophils in a concentration-dependent manner (Figure 3D).

**Lentiviral Transfection**

Chemerin expression in the SCC9, SCC6, SCC15, and Cal27 cell lines was examined by using Western blot analyses (Figure 4A). SCC15 cells were selected for the knock-out of Chemerin with Chemerin-shRNA1# and 2# given their high Chemerin expression levels. The results showed that the Chemerin-shRNA2# was more effective than Chemerin-shRNA1# (Figure 4B). Therefore, Chemerin-shRNA 2# was chosen for the follow-up experiment. Meanwhile, given their low Chemerin expression levels, the Cal27 and SCC9 cell lines were transfected with the Chemerin over-expression lentivirus (Figures 4C, D).

**Neutrophils Promote OSCC Cell Proliferation Through Chemerin**

MTT and colony formation assays were performed to explore the effect of Chemerin and neutrophils on cell proliferation. OSCC cells were transfected with Chemerin-targeting knock-down (over-expression) and/or subjected to combined treatment with neutrophils. The results showed that the growth rate of the neutrophils group was significantly higher than that of the Scr-shRNA group (NC group). The growth rate of the Cal27 and SCC9 cells in the Chemerin over-expression group was significantly higher than that of the NC group. The growth rate of the Cal27 and SCC9 cells in the Chemerin+ neutrophils group was higher than that of the Cal27 and SCC9 cells in the neutrophils group (Figure 5A). Furthermore, the growth rate of the SCC15 cells in the

---

**TABLE 1 | The relationship between the expression of Chemerin, CD15 + TANs density and clinicopathological parameters in OSCC (x / %).**

| Variables                  | n      | @ 1               | @ 2               | @ 3               | Z     | P value |
|----------------------------|--------|-------------------|-------------------|-------------------|-------|---------|
| Sex                        |        |                   |                   |                   |       |         |
| Male                       | 51     | 11 (21.57)        | 20 (39.22)        | 20 (39.22)        | -0.44 | 0.965   |
| Female                     | 23     | 6 (26.09)         | 7 (30.43)         | 10 (43.48)        | -1.225| 0.221   |
| Age                        |        |                   |                   |                   |       |         |
| ≤60 years                  | 40     | 8 (20.00)         | 13 (32.50)        | 19 (47.50)        | -4.293| 0.000*  |
| >60 years                  | 34     | 9 (26.47)         | 14 (41.18)        | 11 (32.35)        | -0.685| 0.493   |
| TNM stage                  |        |                   |                   |                   |       |         |
| UI                         | 37     | 14 (37.84)        | 17 (45.95)        | 7 (18.92)         | -4.789| 0.000*  |
| II,IV                      | 37     | 2 (5.41)          | 12 (32.43)        | 23 (62.16)        | -0.685| 0.493   |
| Differentiation            |        |                   |                   |                   |       |         |
| G1,G2                      | 34     | 8 (23.53)         | 10 (29.41)        | 16 (47.06)        | -4.789| 0.000*  |
| G3                         | 40     | 9 (22.50)         | 17 (42.50)        | 14 (35.00)        | -1.265| 0.206   |
| Lymph node metastasis      |        |                   |                   |                   |       |         |
| Yes                        | 34     | 1 (2.94)          | 10 (29.41)        | 23 (67.65)        | -2.578| 0.010*  |
| No                         | 40     | 16 (40.00)        | 17 (42.50)        | 7 (17.50)         |       |         |
| Tumor size (d/cm)          |        |                   |                   |                   |       |         |
| <4cm                       | 55     | 14 (25.45)        | 21 (38.18)        | 20 (36.36)        |       |         |
| ≥4cm                       | 19     | 3 (15.79)         | 6 (31.58)         | 10 (52.63)        |       |         |
| Tumor recurrence           |        |                   |                   |                   |       |         |
| Yes                        | 27     | 3 (11.11)         | 8 (29.63)         | 16 (59.26)        |       |         |
| No                         | 47     | 14 (29.79)        | 19 (40.43)        | 14 (29.79)        |       |         |

@ 1: strong Chemerin expression + high TANs density group (%).
@ 2: strong Chemerin expression + low TANs density group/weak Chemerin expression + high TANs density group (%).
@ 3: weak Chemerin expression + low TANs density group (%).
P value was estimated by the Mann–Whitney test.
*P < 0.05 was considered to be statistically significant.

**TABLE 2 | The relationship between Chemerin expression and TANs density in OSCC tissues.**

| Chemerin expression | CD15 + TANs density | Spearman’s rho Coefficient test |
|---------------------|---------------------|--------------------------------|
|                     | Low                 | High                           | r     | P value |
| Low                 | 16                  | 9                              | 0.309 |         |
| High                | 20                  | 29                             | 0.175 |         |
Chemerin-shRNA (2#) group was significantly lower than that of the SCC15 cells in the Scr-shRNA group. The effect of neutrophils on cell proliferation was abolished after Chemerin knockdown (Figure 5A). The colony numbers of the Scr-shRNA, Scr-shRNA+ neutrophils, Chemerin-shRNA (2#), and Chemerin-shRNA (2#)+ neutrophils groups of the SCC15 cells were 304.29 ± 35.42, 459.66 ± 38.73, 119.76 ± 32.91, and 154.15 ± 34.35, respectively (Figure 5B). The colony numbers of the Cal27 cells in the NC, NC+ neutrophils, Chemerin, and Chemerin+ neutrophils groups were 110.32 ± 31.41, 176.62 ± 35.53, 200.72 ± 38.91, and 301.35 ± 44.75, respectively, and those of the SCC9 cells in the Scr-shRNA, Scr-shRNA+ neutrophils, Chemerin-shRNA (2#), and Chemerin-shRNA (2#)+ neutrophils groups were 121.62 ± 35.39, 182.42 ± 31.59, 202.41 ± 42.21, and 331.18 ± 38.75, respectively (Figure 5B). These findings indicated that neutrophils promoted the proliferation of OSCC cells via Chemerin.

Flow cytometry was performed to further study the effects of Chemerin and neutrophils on the cell cycle. The cell phase distributions of the Scr-shRNA, Scr-shRNA+ neutrophils, Chemerin, and Chemerin+ neutrophils groups were compared in OSCC patients. The results showed that the proportion of cells in the G0/G1 phase was significantly increased, while the proportion of cells in the S and G2/M phases was decreased in the Chemerin and Chemerin+ neutrophils groups compared to the Scr-shRNA and Scr-shRNA+ neutrophils groups. These findings suggested that Chemerin and neutrophils may promote the proliferation of OSCC cells via the cell cycle.

Table 3: Univariate and multivariate overall survival analysis in OSCC patients.

| Variables                        | Univariate analysis | Regression coefficient | Multivariate analysis |
|----------------------------------|---------------------|------------------------|----------------------|
|                                  | Hazard ratio (95% CI) | P value                | Hazard ratio (95% CI) | P value                |
| Sex                              | -0.174              | 0.841 (0.415–1.702)    | 0.630                |
| Age                              | 0.313               | 1.367 (0.716–2.612)    | 0.343                |
| TNM stage                        | 0.934               | 2.544 (1.292–5.009)    | 0.007*               |
| Differentiation                  | -0.218              | 0.804 (0.422–1.534)    | 0.508                |
| Lymph node metastasis            | 0.841               | 2.319 (1.2–4.482)      | 0.012*               |
| Tumor size                       | 0.148               | 1.16 (0.561–2.396)     | 0.689                |
| Tumor recurrence                 | 0.369               | 1.446 (0.753–2.775)    | 0.268                |
| The expression of Chemerin,      | 0.691               | 1.996 (1.246–3.195)    | 0.004*               |
| CD15 + TANs density              |                      |                        | 1.810 (1.056–3.133)  | 0.031*               |

CI, Confidence interval.
*P < 0.05 was considered to be statistically significant.
Chemerin-shRNA (2#), and Chemerin-shRNA (2#)+ neutrophils groups of SCC15 cells were as follows (Figure 5C): G1 phase: 55.13% ± 1.16%, 51.58% ± 2.71%, 58.34 ± 1.32% and 59.55% ± 2.15%; S phase: 21.67% ± 1.45%, 26.11 ± 2.81%, 17.52% ± 1.74% and 17.81% ± 1.36%; and G2/M phase: 23.2% ± 2.19%, 22.31% ± 3.41%, 24.14% ± 2.08%, and 22.64% ± 1.95%. The proportion of the G1 phase was significantly decreased and the G2/M phase ratio was significantly increased in the Scr-shRNA group compared with those in the neutrophils group. Compared with the Scr-shRNA group, the Chemerin-shRNA (2#) group had a significant reduction in the proportion of cells in the G1 phase and a significant increase in the proportion of cells in the G2/M phase, indicating significant G2/M arrest. The effect of neutrophils on the cell cycle was abolished after Chemerin knock-down. The cell phase distributions of NC, NC+ neutrophils, Chemerin, and Chemerin+ neutrophils Cal27 cells were determined to further confirm these findings and were as follows (Figure 4C): G1 phase: 68.8% ± 2.96%,

### TABLE 4 | Univariate and multivariate disease-free survival analysis in OSCC patients.

| Variables                  | Regression coefficient | Univariate analysis | Multivariate analysis |
|----------------------------|------------------------|---------------------|-----------------------|
|                            |                        | Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value |
| Sex                        | -0.191                 | 0.826 (0.408–1.674)  | 0.597     | 3.861 (0.838–17.79)  | 0.083   |
| Age                        | 0.177                  | 1.194 (0.624–2.285)  | 0.592     | 0.462 (0.095–2.236)  | 0.337   |
| TNM stage                  | 1.907                  | 2.966 (1.508–5.961)  | 0.002*    | 1.351                | 0.083   |
| Differentiation            | -0.335                 | 0.716 (0.374–1.368)  | 0.312     | 0.773                | 0.083   |
| Lymph node metastasis      | 1.022                  | 2.779 (1.423–5.427)  | 0.003*    | -0.773               | 0.592   |
| Tumor size                 | 0.199                  | 1.221 (0.591–2.523)  | 0.591     | 1.026                | 0.748   |
| Tumor recurrence           | 0.516                  | 1.675 (0.87–3.225)   | 0.123     | 0.969                | 0.413   |
| The expression of Chemerin,| 0.968                  | 2.634 (1.588–4.367)  | <0.001*   | 2.405 (1.353–4.273)  | 0.003*  |
| CD15 + TANs density        |                        |                      |           |                      |         |

CI, Confidence interval.

*P < 0.05 was considered to be statistically significant.
58.2% ± 2.01%, 57.5% ± 2.30%, and 49.5% ± 2.110%; S phase: 12.93% ± 2.29%, 19.5% ± 1.87%, and 20.3% ± 2.74%; and G2/M phase: 18.27% ± 2.01%, 22.3% ± 1.65%, 22.2% ± 2.35%, and 23.2% ± 2.25%. The cell phase distributions of the NC, NC+ neutrophils, Chemerin, and Chemerin+ neutrophils SCC9 cells were as follows (Figure 5C): G1 phase: 62.20% ± 1.26%, 56.70% ± 1.01%, 56.1% ± 1.30%, and 51.8% ± 1.45%; S phase: 18.40% ± 1.59%, 27.10% ± 1.87%, 26.2% ± 1.74%, and 34.2% ± 2.71%; and G2/M phase: 19.1% ± 2.09%, 16.2% ± 3.05%, 17.7% ± 2.38%, and 14.0% ± 2.35%.

Neutrophils Promote the Migration, Invasion, and EMT of OSCC Cells Through Chemerin

Transwell assay was used to further investigate the migration and invasion of OSCC cells. The results showed that in the Scr-shRNA, Scr-shRNA+ neutrophils, Chemerin-shRNA (2#), and Chemerin-shRNA (2#)+ neutrophils groups, the numbers of migrated SCC15 cells were 188.67 ± 9.07, 295.67 ± 13.23, 107.67 ± 5.86, and 127.67 ± 10.02 (Figure 6A), respectively, and the numbers of invasive SCC15 cells were 173.56 ± 6.11, 255.00 ± 5.00, 103.47 ± 7.37, and 113.33 ± 6.65 (Figure 6B), respectively. These data suggested that neutrophils promoted cell migration and invasion and that the down-regulation of Chemerin significantly inhibited the migration and invasion of SCC15 cells. Furthermore, the effect of neutrophils on cell migration and invasion was abolished after Chemerin knockdown.

Transwell assays were performed on Chemerin-over-expressing Cal27 and SCC9 cells to further confirm these results. In the NC, NC+ neutrophils, Chemerin, and Chemerin+ neutrophils groups, the numbers of migrated Cal27 (SCC9) cells were 29.33 ± 4.14, 48.67 ± 7.12, 49.00 ± 5.62, and 88.67 ± 5.60 (105.32 ± 9.76, 189.67 ± 10.06, 200.32 ± 9.56, and 339.14 ± 7.02) (Figure 6C), respectively, and the numbers of invasive Cal27 (SCC9) cells were 25.34 ± 6.13, 45.34 ± 5.51, 44.67 ± 6.66, and 81.52 ± 8.08 (79.00 ± 6.56, 151.01 ± 9.07, 143.07 ± 7.94, and 301.67 ± 11.50), respectively (Figure 6D). Therefore, neutrophils may promote the migration and invasion of OSCC cells via Chemerin.
EMT, a well-characterized embryological process, has been identified to play a critical role in tumor metastasis (34–36). We cultured OSCC cells with neutrophils in a previously described co-culture system to explore the role of neutrophils and Chemerin in mediating EMT in OSCC cells.

Chemerin, Slug, Snail, E-cadherin, N-cadherin, and Vimentin were detected in OSCC via Western blot analysis to further examine the effect of Chemerin and neutrophils on EMT. Neutrophils decreased the expression of E-cadherin and increased the expression levels of Chemerin, Slug, Snail, N-cadherin, and Vimentin in the three OSCC cell lines relative to the control group. Compared with those in the Scr-shRNA group, the expression of E-cadherin increased and the expression levels of Chemerin, N-cadherin, Vimentin, Slug, and Snail decreased in the Chemerin-shRNA (2#) SCC15 cells. Moreover, the effects of neutrophils on Chemerin, E-cadherin, N-cadherin, Vimentin, Slug, and Snail significantly decreased after Chemerin knock-down (Figure 6E). This correlation was then confirmed in Cal27 and SCC9 cells (Figures 6F, G), in which Chemerin over-expression further promoted the expression of proteins in the neutrophils group (Figures 7B, C). All these data indicated that neutrophils may regulate the JAK2/STAT3 signaling pathway through Chemerin to promote the proliferation and invasion of OSCC cells.

**Neutrophils Activate the JAK2/STAT3 Signaling Pathway in OSCC Cells Through Chemerin**

We used Western blot analysis to examine the expression levels of JAK2, p-JAK2, STAT3, p-STAT3, Phospho-Rb, E2F1, CyclinE1, and CyclinD1 in the Scr-shRNA, Scr-shRNA + neutrophils, Chemerin-shRNA (2#), and Chemerin-shRNA (2#)+neutrophils groups of SCC15 cells and the NC, NC+ neutrophils, Chemerin, and Chemerin+ neutrophils groups of Cal27(SCC9) cells to investigate whether JAK2/STAT3 signaling is involved in the interaction between neutrophils and Chemerin in OSCC cells in the co-culture system. We found that neutrophils increased the expression levels of p-JAK2, p-STAT3, Phospho-Rb, E2F1, CyclinE1, and CyclinD1 in the three OSCC cells relative to those in the control group. p-JAK2, p-STAT3, Phospho-Rb, E2F1, CyclinE1, and CyclinD1 levels decreased in the Chemerin-shRNA (2#) SCC15 cells relative to those in the Scr-shRNA group. Moreover, the effects of neutrophils on p-JAK2, p-STAT3, Phospho-Rb, E2F1, CyclinE1, and CyclinD1 significantly decreased after Chemerin knockdown (Figure 7A). This correlation was then confirmed through Chemerin over-expression in Cal27 and SCC9 cells, in which Chemerin over-expression further promoted the expression of proteins in the neutrophils group (Figures 7B, C). All these data indicated that neutrophils may regulate the JAK2/STAT3 signaling pathway through Chemerin to promote the proliferation and invasion of OSCC cells.

**DISCUSSION**

Neutrophils are the most abundant subpopulation of leukocytes that provide the first line of defense against invading pathogens. Studies have found that TANs have multiple functions in the tumor microenvironment (6). Depending on the tumor microenvironment, TANs may affect tumor progression through cytokines and chemokines with tumor-promoting or antitumor functions (7). Chemerin is a chemoattractant and a novel multifunctional adipokine. It plays an important role in regulating inflammation, angiogenesis, fat metabolism, cell proliferation, migration, and chemotaxis (37–40). However, the possible roles of Chemerin expression and neutrophils in OSCC have not been experimentally verified.
Chemokines are important components of cancer-related inflammatory conditions that promote tumor progression in many ways; these conditions include leukocyte recruitment and function, tumor cell proliferation, invasion, and metastasis (41–43). Previous research has demonstrated that Chemerin induces the chemotaxis of immune cells, such as immature dendritic cells, resident macrophages, and cytotoxic natural killer cells, to inflammatory sites (44). We used the Transwell assay to explore the possible chemotactic effects of Chemerin from tumor cells on neutrophils. Our results showed that all three OSCC cell lines exhibited enhanced chemotaxis to neutrophils, and SCC15, which had the highest Chemerin level, had the greatest chemotactic effect. R-Chemerin also improved chemotaxis to neutrophils in a concentration-dependent manner. Additionally, our double-staining IHC results revealed that Chemerin expression demonstrated great heterogeneity in OSCC tissues and that TANs infiltration was increased in areas with strong Chemerin expression. Spearman’s rho coefficient test indicated that Chemerin expression was positively related to the density of CD15+ TANs in OSCC tissues. Strong Chemerin expression+ high TANs density was associated with lymph node metastasis, high clinical stage, and tumor recurrence. This association indicated that strong Chemerin expression+ high TANs density may predict poor clinical outcomes. Moreover, survival analysis illustrated that strong Chemerin expression+ high TANs density was related to shortened overall and disease-free survival and that each factor was an independent prognostic factor of patients with OSCC. These results implied that Chemerin over-expression in OSCC may attract additional neutrophils to tumor sites and promote neutrophil-mediated tumor progression.

EMT is a key step for tumor cells to obtain enhanced invasive and metastatic capabilities; this step is characterized by the loss of connections and the acquisition of mesenchymal properties, such as motility and invasiveness, by epithelial cells (45). Tumor cells use EMT as an intermediate phenotype to achieve self-renewal and adapt to their microenvironment (46, 47). Previous works have found that EMT can be induced not only by the loss of cell contact (for example, due to the degradation of the basement membrane or other changes in the microenvironment) but also by a variety of cytokines, such as TGF-β (48). Neutrophils can induce EMT in OSCC. However, the molecular mechanism of this effect is poorly understood. In the tumor microenvironment, a large number of cytokines and chemokines, such as IL-1β, IL-6, IL-8, and TNFα,
CyclinE1, and CyclinD1 (52). STAT3 signaling through Chemerin and then up-regulated JAK2/STAT3 pathway and further promoted tumor migration and invasion via EMT. So we believe that neutrophils may promote tumor progression (proliferation and invasion) via regulating EMT and JAK2/STAT3 signaling through Chemerin in oral squamous cell carcinoma.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

This study was performed in line with the principles of the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study. Written informed consent for publication was obtained from the patients enrolled in the study. Approval was granted by the ethics committee of The Affiliated Hospital of Qingdao University (10.14.2020/ QYFYWZLL25964). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

XH and NW conceived and designed the study. FX, YF, FG, SG and XZ collected clinical data. XH and NW wrote the manuscript. All authors have reviewed the final version of the manuscript and approved its submission for publishing.

FUNDING

This study was funded by NW (National Natural Science Foundation of China, Grant Number: 81702677) and CW (National Natural Science Foundation of China, grant 81602320).

ACKNOWLEDGMENTS

I would like to thank NW, FG, FX, etc. for their help in this research, as well as Qingdao University, Pingxiang People’s Hospital and Affiliated Hospital of Qingdao University for their support to this research. The authors thank the patients and clinical staff for their assistance in this study.

REFERENCES

1. Coussens LM, Werb Z. Inflammation and Cancer. *Nature* (2002) 420 (6917):860–7. doi: 10.1038/nature01322
2. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Frontiers in Oncology | www.frontiersin.org January 2022 | Volume 12 | Article 812044 12
3. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. *Cell* (2011) 144(5):646–74. doi: 10.1016/j.cell.2011.02.013
4. Quail DF, Joyce JA. Microenvironmental Regulation of Tumor Progression and Metastasis. *Nat Med* (2013) 19(11):1423–37. doi: 10.1038/nm.3394
5. Magalhaes MA, Glogauer JE, Glogauer M. Neutrophils and Oral Squamous Cell Carcinoma: Lessons Learned and Future Directions. *J Leukoc Biol* (2014) 96(5):695–702. doi: 10.1189/jlb.4RU0614-294R
6. Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. Tumor Associated Macrophages and Neutrophils in Tumor Progression. *J Cell Physiol* (2013) 228(7):1404–12. doi: 10.1002/jcp.24260
7. Tecchio C, Scapini P, Pizzolo G, Cassatella MA. On the Cytokines Produced by Human Neutrophils in Tumors. *Semin Cancer Biol* (2013) 23(3):159–70. doi: 10.1016/j.semcancer.2013.02.004
8. Li C, Zhao L, Wang Q, Ma S, Sun J, Ma C, et al. Neutrophils Infiltration and Its Correlation With Human Papillomavirus Status in the Oral Squamous Cell Carcinoma. *Cancer Manag Res* (2019) 11:5171–85. doi: 10.2147/CMAR.S202465
9. Wang N, Feng Y, Wang Q, Liu S, Xiang L, Sun M, et al. Neutrophils Infiltration in the Tongue Squamous Cell Carcinoma and Its Correlation With CEACAM1 Expression on Tumor Cells. PloS One (2014) 9(2):e89991. doi: 10.1371/journal.pone.0089991
10. Sotiropoulos GP, Dalamaga M, Antonakos G, Marinou I, Vogiatzakis E, Kotopouli M, et al. Chemerin as a Biomarker at the Intersection of Inflammation, Chemotaxis, Coagulation, Fibrinolysis and Metabolism in Resectable non-Small Cell Lung Cancer. Lung Cancer (2018) 125:291–9. doi: 10.1016/j.lungcan.2018.10.010
11. Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016.
12. Lamouille S, Xu J, Derynck R. Molecular Mechanisms of Epithelial-Mesenchymal Transition. Nat Rev Mol Cell Biol (2014) 15(3):178–96. doi: 10.1038/nrm3758
13. Singh R, Mandhani A, Agrawal V, Garg M. Positive Correlation Between Matrix Metalloproteinases and Epithelial-To-Mesenchymal Transition and its Association With Clinical Outcome in Bladder Cancer Patients. Cancer Microenvion (2018) 11(1):23–39. doi: 10.1007/s12307-017-0199-4
14. Puisieux A, Brabletz T, Caramel J. Oncogenic Roles of EMT-Inducing Transcription Factors. Nat Cell Biol (2014) 16(6):488–94. doi: 10.1038/ncb2976
15. Diepenbruck M, Christofori G. Epithelial-Mesenchymal Transition (EMT) and Metastasis: Yes, No, Maybe? Curr Opin Cell Biol (2016) 43:7–13. doi: 10.1016/j.ceb.2016.06.002
16. Mittal V. Epithelial Mesenchymal Transition in Aggressive Lung Cancers. Adv Exp Med Biol (2016) 890:37–56. doi: 10.1007/978-3-319-24932-2_3
17. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, et al. Epithelial-To-Mesenchymal Transition Is Dispensable for Metastasis But Induces Chemoresistance in Pancreatic Cancer. Nature (2015) 527(7579):525–30. doi: 10.1038/nature16064
18. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated Regulation of Myeloid Cells by Tumours. Nat Rev Immunol (2012) 12(4):253–68. doi: 10.1038/nri3175
19. Ferland DJ, Watts SW. Chemerin: A Comprehensive Review Elucidating the Need for Cardiovascular Research. Pharmacol Res (2015) 99:351–61. doi: 10.1016/j.phrs.2015.07.018
20. Bondue B, Wittamer V, Parmentier M. Chemerin and its Receptors in Leukocyte Trafficking, Inflammation and Metabolism. Cytokine Growth Factor Rev (2011) 22(5-6):331–8. doi: 10.1016/j.cytogfr.2011.11.004
21. Tummler C, Snapkov I, Wickstrom M, Moens U, Ljungblad L, Maria Elfman et al. Chemerin as a Biomarker at the Intersection of Inflammation, Chemotaxis, Coagulation, Fibrinolysis and Metabolism in Resectable non-Small Cell Lung Cancer. Lung Cancer (2018) 125:291–9. doi: 10.1016/j.lungcan.2018.10.010
22. Wang N, Wang Q, Chi J, Xiang F, Lin M, Wang W, et al. Carcinogenicmycin Antigen Cell Adhesion Molecule 1 Inhibits the Antitumor Effects of Neutrophils in Tongue Squamous Cell Carcinoma. Cancer (2019) 110 (2):319–29. doi: 10.1111/cas.13969
23. Hao Y, Baker D, Ten Dijke P. TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. Int J Mol Sci (2019) 20(11):2767. doi: 10.3390/ijms20112767
24. Chaffer CL, San Juan BP, Lim E, Weinberg RA. EMTCell Plasticity and Metastasis. Cancer Metastasis Rev (2016) 35(4):645–54. doi: 10.1007/s10555-016-9648-7
25. Bakir B, Chiarella AM, Pitareesi JR, Rustgi AK. EMT, MET, Plasticity, and Tumor Metastasis. Trends Cell Biol (2020) 30(10):764–76. doi: 10.1016/j.tcb.2020.07.003
26. Sell H, Laurentieliene J, Taube A, Eckardt K, Cramer A, Horrigs A, et al. Chemerin is a Novel Adipocyte-Derived Factor Inducing Insulin Resistance in Primary Human Skeletal Muscle Cells. Diabetes (2009) 58(12):2731–40. doi: 10.2337/db09-0277
27. Mariani F, Roncucci L. Chemerin/chemR23 Axis in Inflammation Onset and Resolution. Inflamm Res Off J Eur Histamine Res Soc (2015) 64(2):85–95. doi: 10.1007/s00011-014-0792-7
28. Kaur J, Adya R, Tan BK, Chen J, Randeva HS. Identification of Chemerin Receptor (ChemR23) in Human Endothelial Cells: Chemerin-Induced Endothelial Angiogenesis. Biochem Biophys Res Commun (2010) 391(4):1762–8. doi: 10.1016/j.bbrc.2009.12.150
29. Erdogan S, Yilmaz FM, Yazici O, Yozgat A, Sezer S, Ozdemir N, et al. Inflammation and Chemerin in Colorectal Cancer. Tumour Biol (2016) 37(5):6327–40. doi: 10.1007/s13277-015-4483-y
30. Nishida J, Momoi Y, Miyakuni K, Tamura Y, Takahashi K, Koinuma D, et al. Epigenetic Remodelling Shapes Inflammatory Renal Cancer and Neutrophil-Dependent Metastasis. Nat Cell Biol (2020) 22(4):465–75. doi: 10.1038/s41556-020-0491-2
31. Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The Chemokine System in Cancer Biology and Therapy, Cytokine Growth Factor Rev (2010) 21(2):27–39. doi: 10.1016/j.cytogfr.2009.11.007
32. Nagarsheth N, Wicha MS, Zou W. Chemokines in the Cancer Microenvironment and Their Relevance in Cancer Immunotherapy. Nat Rev Immunol (2017) 17(9):559–72. doi: 10.1038/nri.2017.49
33. Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I, et al. STAT3 Activation Abrogates Growth Factor Dependence and Contributes to Head and Neck Squamous Cell Carcinoma Tumor Growth In Vivo. Cell Growth Differ (2002) 13(8):55–62.
34. Leeman RJ, Lui VW, Grandis JR. STAT3 as a Therapeutic Target in Head and Neck Cancer. Expert Opin Biol Ther (2006) 6(3):231–41. doi: 10.1517/14712598.6.3.231
48. Kalluri R, Weinberg RA. The Basics of Epithelial-Mesenchymal Transition. *J Clin Invest* (2009) 119(6):1420–8. doi: 10.1172/JCI39104

49. Zhang W, Gu J, Chen J, Zhang P, Ji R, Qian H, et al. Interaction With Neutrophils Promotes Gastric Cancer Cell Migration and Invasion by Inducing Epithelial-Mesenchymal Transition. *Oncol Rep* (2017) 38(5):2959–66. doi: 10.3892/or.2017.5942

50. An X, Liu J, Li Y, Dou Z, Li N, Suo Y, et al. Chemerin/CMKLR1 Ameliorates Nonalcoholic Steatohepatitis by Promoting Autophagy and Alleviating Oxidative Stress Through the JAK2-STAT3 Pathway. *Peptides* (2021) 135:170422. doi: 10.1016/j.peptides.2020.170422

51. Bromberg J, Wang TC. Inflammation and Cancer: IL-6 and STAT3 Complete the Link. *Cancer Cell* (2009) 15(2):79–80. doi: 10.1016/j.ccr.2009.01.009

52. Kuo YY, Lin HP, Huo C, Su LC, Yang J, Hsiao PH, et al. Caffeic Acid Phenethyl Ester Suppresses Proliferation and Survival of TW2.6 Human Oral Cancer Cells via Inhibition of Akt Signaling. *Int J Mol Sci* (2013) 14(5):8801–17.

53. Yin Y, Tan Y, Yao Y, Lu N, Zhang F. SNHG12/miR-326/E2F1 Feedback Loop Facilitates the Progression of Oral Squamous Cell Carcinoma. *Oral Dis* (2020) 26(8):1631–9. doi: 10.1111/odi.13458

54. Li Y, Wang Y, Li J, Ling Z, Chen W, Zhang L, et al. Tacrolimus Inhibits Oral Carcinogenesis Through Cell Cycle Control. *BioMed Pharmacother* (2021) 139:111545. doi: 10.1016/j.biopha.2021.111545

55. Jiang Q, Cao Y, Qiu Y, Li C, Liu L, Xu G. Progression of Squamous Cell Carcinoma Is Regulated by miR-139-5p/CXCR4. *Front Biosci (Landmark Ed)* (2020) 25:1732–45. doi: 10.2741/4875

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Hu, Xiang, Feng, Gao, Ge, Wang, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.